




GORE® VIABAHN®

Endoprosthesis with PROPATEN Bioactive Surface^a

GORE REVISE CLINICAL STUDY



Together, improving life

^a As used by Gore, PROPATEN Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface.

Gore REVISE Clinical Study


Multicenter, prospective, randomized evaluation of the VIABAHN® Device at the venous anastomosis of arteriovenous (AV) grafts versus percutaneous transluminal angioplasty (PTA).

The REVISE Study is the only study to include an endoprosthesis across the elbow and the only randomized control trial to include thrombosed grafts.¹⁻⁴


Results and key takeaways: Patency

The VIABAHN® Device had nearly 50% higher primary patency at 6 months than PTA alone.⁵

Target lesion⁵




Circuit⁵



Increased primary patency of both the target lesion and the circuit by ~ 50% when compared to PTA at 6 months.⁵

The VIABAHN® Device demonstrated secondary patency across the elbow at 2 years of 83% with 0 reported fractures.⁶

Image courtesy of William DaVanzo, MD. Used with permission.




Results and key takeaways: Thrombosed grafts

Thrombosed graft lesions treated with the VIABAHN® Device required fewer reinterventions versus PTA at 2 years.⁷



40% fewer
reinterventions⁷

Reinterventions⁷




Fewer reinterventions drove lower costs versus PTA in the US⁷



18% reduction
in total lesion
treatment costs⁷

Total costs⁷



Compared to total two-year treatment costs with PTA only (\$37,206), treatment with the VIABAHN® Device (\$30,329) becomes more cost-effective at 15 months post-placement, generating \$6,877 in total cost savings per patient.^{b,7}

^b Costs are reflected in 2015 USD

References

1. W. L. Gore & Associates, Inc. GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis (REVISE). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine; 2014. <https://clinicaltrials.gov/ct2/show/NCT00737672>. Published August 15, 2008. Updated October 14, 2014. September 11, 2019. NLM Identifier: NCT00737672.
2. Flair® Endovascular Stent Graft [Instructions for Use]. Tempe, AZ: C. R. Bard, Inc; 2014. B05659 Rev.3/08-14.
3. Covera® Vascular Covered Stent [Instructions for Use]. Tempe, AZ: C. R. Bard Peripheral Vascular; 2018. B05872. Rev4/ 08-18.
4. Haskal ZJ, Trerotola S, Dolmatch B, et al. Stent graft versus balloon angioplasty for failing dialysis-access grafts. *New England Journal of Medicine* 2010;362(6):494-503.
5. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. *Journal of Vascular Surgery* 2016;64(5):1400-1410.e1. <https://www.sciencedirect.com/science/article/pii/S0741521416301756>
6. W. L. Gore & Associates, Inc. GORE® VIABAHN® Endoprosthesis versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients. (GORE REVISE Study, AVR 06-01). Flagstaff, AZ: W. L. Gore & Associates, Inc; 2012. [IDE Final Clinical Study Report]. G070069.
7. Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE; REVISE Investigators. Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial. *Journal of Vascular & Interventional Radiology* 2019;30(2):203-211.e4.



Refer to *Instructions for Use* at elifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only

Products listed may not be available in all markets.

© 2025 W. L. Gore & Associates, Inc. All rights reserved. All trademarks referenced are trademarks of either a member of the Gore group of affiliated companies or their respective owners. "Together, improving life" mark and design are trademarks of a Gore company. 25PL1089-EN01 AUGUST 2025

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

